Cardiol Therapeutics (CRDL) Total Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (changed N/A YoY), and the FY2023 full-year result was $3.6 million, down 21.99% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $3.2 million, down from $5.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $5.6 million in Q1 2024, with the low at $2.7 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $4.0 million across 4 years, with a median of $3.9 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 455.96% — and 2023, when it plunged 36.29%.
• Cardiol Therapeutics' Total Non-Current Liabilities stood at $4.6 million in 2022, then declined by 21.99% to $3.6 million in 2023, then surged by 54.52% to $5.6 million in 2024, then slumped by 42.95% to $3.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.2 million (Q1 2026), $5.6 million (Q1 2024), and $3.6 million (Q4 2023), per Business Quant data.